India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding.
“What we really do is we took the most constrained, complex, and costly medical imaging solution in radiology, and we supplanted it with what is the most accessible, simple and affordable, which is CT,” Sean Walsh, RADiCAIT’s CEO told TechCrunch.
The company’s so-called Pathfinder software can look at almost anything — buildings, tree-lined roads, even aerial views — and quickly match it to a database and generate real-time navigation.
“What we really do is we took the most constrained, complex, and costly medical imaging solution in radiology, and we supplanted it with what is the most accessible, simple and affordable, which is CT,” Sean Walsh, RADiCAIT’s CEO told TechCrunch.
Although Maxim was convinced that gene therapy could reverse PKD, the biggest hurdle was creating a mechanism to deliver the drugs directly to the diseased cells.
If you’re not able to attend in person, the next best thing is to check out our livestream of the Disrupt Stage. Tune in right here starting at 10 a.m. PT.
Mercor, which connects AI labs with domain experts for training their foundational AI models, is close to raising $350 million at a $10 billion valuation.
Mercor, which connects AI labs with domain experts for training their foundational AI models, is close to raising $350 million at a $10 billion valuation.
Pinterest is testing an AI-driven collage to help users create outfits from saved Pins and personalized boards curated with AI.
These 20 companies are more than just early-stage startups — they’re the architects of what’s next. And they’ll have just six minutes on the Disrupt Stage to prove it.
